Sleep Medications in Primary Care

Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC, FNAP President, Fitzgerald Health Education Associates, North Andover, MA Family Nurse Practitioner, Greater Lawrence (MA) Family Health Center Editorial Board Member *The Nurse Practitioner Journal, The Prescriber's Letter, American Nurse Today* Member, Pharmacy and Therapeutics Committee Neighborhood Health Plan, Boston, MA

Disclosure

- No real or potential conflict of interest to disclose.
- No off-label, experimental or investigational use of drugs or devices will be presented.

Fitzgerald Health Education Associates

Objectives

- Upon completion of the learning activity the participant will be able to:
 - Describe the process of naturallyoccurring sleep.
 - Identify the pharmacokinetics and pharmacodynamics of medications and herbal products to enhance sleep.

Fitzgerald Health Education Associates

Objectives (continued)

- Upon completion of the learning activity the participant will be able to: (cont.)
 - Recognize the anticipated sleep outcomes with select medications commonly prescribed or used to enhance sleep as well as the risks associated with these products.

Fitzgerald Health Education Associates

Sleep Defined (Or Best Defined in its Absence?)

- Difficult to define and characterized by observable changes in behavior and responsiveness
 - -Decreased activity
 - -Recognizable posture

Fitzgerald Health Education Associates


- Brain is less attentive to external stimuli
- Altered consciousness yet easily aroused
 - http://healthysleep.med.harvard.edu/healthy/science/what/characteristics


Insomnia: The Cost of the Problem

- Costs the average American worker -11.3 days per year, \$2,280 in lost
 - productivity each yearPresenteeism vs. absenteeism
- Entire USA

Fitzgerald Health Education Associates

- \$63.2 billion in lost productivity - Source: http://healthland.time.com/2011/09/01/the-high-costof-bad-sleep-63-billion-per-year/





Insomnia Disorders (continued)

- Dissatisfaction with sleep defined
 - -Difficulty initiating and/or maintaining sleep
 - -Non-restorative sleep

Fitzgerald Health Education Associates

-≥3 nights per week for ≥3 months, despite adequate opportunity to sleep

Insomnia Disorders (continued)

- Significant negative impact on daytime functioning defined
 - -Significant fatigue
 - Sleepiness
 - Poor concentration
 - -Low mood
 - Impaired ability to perform social, occupational or caregiving responsibilities
- Not explained by other health issues
- Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.


Cognitive Behavioral Therapy (CBT) for Insomnia

Consider medications as an aid to gap while working with patient on CTB.

Resources: <u>http://www.mentalhealth.va.gov/coe/cih-</u> <u>visn2/Documents/Provider_Education_Handouts/CBT_for_Inso</u> <u>mnia_Information_Sheet_for_BHPs_Version_3.pdf</u>

http://www.sleepeducation.org/treatment-therapy/cognitivebehavioral-therapy The focus of this program is medications used to induce/maintain sleep.

Assumed that the NP has appropriately assessed the patient and that a sleep medication is a prudent clinical action with risks and benefits shared with patient



Caffeine's Pharmacokinetics Clinical Significance?

- MW=194.19
- Lipophilic
- T_{1/2} range=1.5-9 h


Fitzgerald Health Education Associates

- C_{max}=~15-100 mins
- Minimum first-pass effect
- CYP 450 substrate 1A2 - Source: http://books.nap.edu/openbook.php?isbn=0309082587


True or false?


- When compared with a healthy 40-year-old adult, CYP 450 isoenzyme levels can drop by up to 30% in elders after age 70 years.
- CYP 450 1A2's activity is influenced by the presence or absence of estrogen in women.


Fitzgerald Health Education Associates





17












<text><text><figure>



Potential Influence of Sleep Aids on Sleep Architecture: Potential Increase in Stage 1, Stage 2 Sleep Potential Reduction in Stage 3, Stage 4, REM Sleep

Consider as short-term therapy!

Source: http://www.medscape.com/viewarticle/723907_2

Sleep-Wake Homeostasis

- The pressure to sleep – Also known as sleep drive
- Unable to overcome

Fitzgerald Health Education Associates

- With use of stimulants, can only mask need to sleep
- -With medications, can mildly promote or enhance sleep drive

30

32

Pharmacology of Insomnia Treatment Therapeutic Approaches

- Stimulate/activate sleep-promoting system
 - -GABA
 - Inhibitory neurotransmitter (NT)
 - Main hypothalamic NT, projects to several sleep-regulating centers of the brain – Increase in GABA inhibits ("blocks") the wakepromoting chemicals
 - Melatonin

Fitzgerald Health Education Associates

Pharmacology of Insomnia Treatment Therapeutic Approaches (continued)

- Suppress the wake-promoting systems
 - Histamine
 - Cholinergic
 - Serotonin

Fitzgerald Health Education Associates

-Orexin


In particular, for sleep medications that induce sedation, what is the medication's half-life $(T_{1/2})$?

How much of the medication will be on board upon AM awakening?

Onset of action?

Peak of action?

Reference: PL Detail-Document, Comparison of Insomnia Treatments. Pharmacist's Letter/Prescriber's Letter. May 2012.



Fitzgerald Health Education Associates

What % is left of original drug dose? • 1 $T_{\frac{1}{2}}$ - 50% left • 2 $T_{\frac{1}{2}}$ - 50% of 50%=25% left • 3 $T_{\frac{1}{2}}$ - 50% of 50% of 50%=12.5% left • 4 $T_{\frac{1}{2}}$ - 50% of 50% of 50% of 50%=6.25% left • 5 $T_{\frac{1}{2}}$ - 50% of 50% of 50% of 50% of 50%=3.125% left

Fitzgerald Health Education Associates

True or false?
The T_{1/2} of a medication is a predictable number regardless of the patient's age, gender, and overall state of health.

• If a sleep med is taken at 10 PM and has a $T_{\frac{1}{2}}$ of about 2 h, then approximately 6.5% of the original dose will be on board with 6 AM awakening.

True or false?

- In order to exploit optimal PK, all sleep medications should be taken on an empty or near-empty stomach.
- When taken with a meal, the onset of sleep latency with many sleep meds will be delayed by 1.5–3.5 h.

Fitzgerald Health Education Associates

With Many if Not Most Sleep Meds

- When coadministered with alcohol - Additive psychomotor impairment
- Habituation/misuse
 - -Reported in most clinical trials
 - -Controlled substance


Fitzgerald Health Education Associates


• Most are Schedule 4 with exception of psychotropics used for conditions other than sleep, OTCs, herbal products

Fitzgerald Health Education Associates

What would you want to prescribe, if appropriate, for the patient who states,

- "I have an 8-h overnight flight where I need to walk off the plane and go right to an important meeting. Can I have something to help me get some shut-eye on the plane?"
- "My patient is in a subacute care hospital for a few days and cannot fall asleep. Once asleep, he stays asleep fairly well."







FDA Drug Safety Communication: Risk of nextmorning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem, available at http://www.fda.gov/drugs/drugs/drugsafety/ucm334033.htm

From FDA Advisory

- Dosing
 - Recommended zolpidem immediate-release dose: 5 mg for women and either 5 mg or 10 mg for men
 - Recommended zolpidem extended-release dose: 6.25 mg for women and either 6.25 or 12.5 mg for men
 - CR formulation=Special warning about next-day performance issues
 - -Higher doses should be used with caution.

Fitzgerald Health Education Associates

Zolpidem Tartrate Specifically Labeled for Middle-of-the-night Awakening with ≥4 h Sleep Duration Available

- Dose
 - -Men=3.5 mg
 - -Women=1.75 mg

Fitzgerald Health Education Associates

- Only one dose per night, only if needed
 - Source: Intermezzo[®] Prescribing Information, available at http://app.purduepharma.com/xmlpublishing/pi.aspx?id=i

What would you want to prescribe, if appropriate, for the patient who states, "I fall asleep with that sleep med you gave me, but I do not stay asleep. I am back up at 4 AM."

NB: Consider possible contribution of depression.

Longer $T_{\frac{1}{2}}$ Onset of Action=~30 mins Peak=~1h

Eszopiclone


- $-T_{1/2}=6$ h in adults, 9 h in elders
 - Taken at 10 PM=50% of dose on board at 4 AM
- -Dose=Start with 1 mg, can increase to
- 2-3 mg if needed


Fitzgerald Health Education Associates

Common to all Sedative-hypnotics: FDA Advisory


FDA Warning in Patient Drug Information


 "...sedative-hypnotic drug products, a class of drugs used to induce and/or maintain sleep, strengthen their product labeling to include stronger language concerning potential risks. These risks include severe allergic reactions and complex sleep-related behaviors, which may include sleep-driving. Sleep-driving is defined as driving while not fully awake after ingestion of a sedative-hypnotic product, with no memory of the event."








BZD Pharmacokinetics Appropriate Sleep Aids?						
	Dose equivalent	Half-life in hours				
Alprazolam (Xanax [®])	0.5	6-20				
Chlordiazepoxide (Librium [®])	10	30-100				
Clonazepam (Klonopin [®])	0.25	18-50				
Clorazepate (Tranxene [®])	7.5	30-100				
Diazepam (Valium [®])	5	30-100				
Lorazepam (Ativan [®])	1	10-20				
Oxazepam (Serax [®])	15	8-12				
Source: http://www.vhpharmsci.com/vhformulary/tools/benzodiazepines-comparison.htm						
Fitzgerald Health Education Associates	1	51 51				












Suvorexant Recommended Dose

- How supplied
 - -5 mg, 10 mg, 15 mg, and 20 mg tablets
- Recommended daily dose

Fitzgerald Health Education Associates

- -10 mg, taken \geq 30 mins prior to bedtime, only if \geq 7 h of sleep time available, only 1 dose per night
 - If 10 mg dose is well-tolerated but not effective, dose can be increased up to a maximum dose of 20 mg daily.



Suvorexant Adverse Effects and Precaution (continued) • Patient advised about these in handout provided with medication –CNS depressant effects and

- daytime impairment
- -Abnormal thinking and behavioral changes
- -Worsening of depression/suicidal ideation
- Sleep paralysis, hallucinations, cataplexylike symptoms

Fitzgerald Health Education Associates

Fitzgerald Health Education Associates

Antidepressants as Sleep Medications Potential Advantages: Not scheduled, possibly less abuse potential, low cost Potential Disadvantages: Adverse effects


Two Patients Possible TCA or Trazodone Candidates

- A 60-year-old woman with DM neuropathy with partial improvement with pregabalin, difficulty initiating and maintaining sleep in part due to leg burning
- A 56-year-old man with 30-year hx alcohol abuse, now sober × 5 years, difficulty initiating and maintaining sleep

Commonly-prescribed Psychotropic Medications

- Tricyclic antidepressants (TCA)
 - Block reuptake of NE, 5-HT
 Amitriptyline, nortriptyline
- Issues with use
 - -Significant AE in overdose

- -Sedating, possibly helpful with chronic pain
- -Inexpensive



Action of Psychotropic Medications (Katzung, 2014)						
Drug	Sedation or activation	Anti- cholinergic	Serotonin	NE	Dopamine	
Amitriptyline	Sedation +++ Activation 0	++++	+++	++	0	
Nortriptyline	Sedation ++ Activation 0	++	+++	++	0	
Trazodone	Sedation +++ Activation 0	0	0/+	0	0	
Mirtazapine	Sedation ++++	+	0	0	0	
++++ Activation 0 Fitzgerald Health Education Associates 64						

Adverse Effects Meds with Anticholinergic Effect

- Dry as a bone (dry mouth)
- Red as a beet (flushing)
- Mad as a hatter (confusion)
- Hot as a hare (hyperthermia)
- Can't see (vision changes)
- Can't pee (urinary retention)
- Can't spit (dry mouth)
- Can't (something that rhymes with spit) (constipation)

Fitzgerald Health Education Associates

American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults

> Available at: <u>http://onlinelibrary.wiley.com/doi/10.1111/jgs</u> .13702/abstract

Doxepin (Silenor[®])

- Tricyclic antidepressant
 - -FDA-approved as sleep aid
 - -Significant systemic anticholinergic effect
- PK parameters
 - $-T_{max}$ =3.5 h post dose when taken on an empty stomach
 - Doubled when taken with a high-fat meal, labeled warning


Fitzgerald Health Education Associates




Doxepin (Silenor®) (continued)

• Recommended dose

- -3 mg (elder) or 6 mg (adult)
 - Per Beers Criteria, do not Rx ≥6 mg in the older adult
- -Take within 30 mins of going to bed
- Do not take within 3 h of a meal
 Alters PK





Mirtazapine (continued)

- Not FDA-approved for insomnia

 Some evidence on reducing insomnia in depression, especially early in treatment
 - Increases the risk of restless leg syndrome and periodic limb movements in sleep

(Katzung and	Trevor, Basic a	nd Clinical Pl	narmacolog	y, 13 ^t	^h ed. 2014
Drug	Sedation or activation	Anti- cholinergic	Serotonin	NE	Dopamin
Amitriptyline	Sedation +++ Activation 0	++++	+++	++	0
Nortriptyline	Sedation ++ Activation 0	++	+++	++	0
Trazodone	Sedation +++ Activation 0	0	0/+	0	0
Mirtazapine	Sedation ++++ Activation 0	+	0	0	0

Second-generation Antipsychotics (SGA, AKA Atypicals) as Sleep Aids

Sleep-inducing due to largely antihistamine and serotonin effect. Potential drugs of abuse ("Baby Heroin," etc.) Is there a therapeutic indication for use of these meds beyond sleep?

SGAs as Sleep Aids The evidence -Particularly more sedating members of the class demonstrated to be helpful in the presence of schizophrenia -Not extensively studied in unipolar depression as a sleep aid - Source: <u>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC487011/</u> Fitzgerald Health Education Associates

SGA: Most Sedating= Greater H1 Antagonism • H1 antagonism=possible weight gain -Clozapine (Clozaril®) • Seldom used for sleep due to need for WBC monitoring due to neutropenia risk -Olanzapine (Zyprexa[®]) -Quetiapine (Seroquel[®]) -Risperidone (Risperdal®) Source: Comparison of atypical antipsychotics. *Pharmacist's Letter/Prescriber's Letter*. July 2015;310701.

Fitzgerald Health Education Associates

Less Sedating SGA=Less Antihistaminic Effect=Less Weight Gain

- But how helpful for sleep?
 - -Ziprasidone (Geodon[®])
 - -Aripiprazole (Abilify®)
 - -Asenapine (Saphris[®])
 - -Lurasidone (Latuda[®])
 - Paliperidone (Invega[®]) Source: Comparison of atypical antipsychotics. *Pharmacist's* Letter/Prescriber's Letter. July 2015;310701.

Fitzgerald Health Education Associates

SGA PKs: When should the med be taken if used to enhance sleep?

- Olanzapine PK
 - -Plasma peak=6 h post dose

Ouetiapine

SGA PKs: When should the med be taken if used to enhance sleep? (continued)

• Risperidone

- PK related to CYP 2D6 activity
 - Plasma peak in extensive metabolizers=3 h

81

- Plasma peak in poor metabolizers=17 h
- $T_{1/2}$ in extensive metabolizers= 3 h
- T_{1/2} in poor metabolizers=20 h

-Plasma peak with IR formulation=1.5 h $-T_{1/2}=6$ h Fitzgerald Health Education Associates Fitzgerald Health Education Associates Source: Ann Pharmacother. 2012;46:718-22.

• "There are potential safety concerns when using low-dose quetiapine for treatment of insomnia. These concerns should be evaluated in further prospective studies. Based on limited data and potential safety concerns, use of low-dose quetiapine for insomnia is not recommended." Antihistamines Sold OTC, Significant Anticholinergic Effect


> Avoid in elders. Dangerous in overdose Best candidate is younger adult with temporary issue with sleep.

Antihistamines as Sleep Aids

• Potential tolerance

Fitzgerald Health Education Associates


- -Most often noted with ≥ 10 nights/use
- Consider an "off" night after three days of use to reduce tolerance.
- Avoid using more than ten days without consulting a healthcare professional.



- Hydroxyzine (Vistaril[®], Atarax[®])
 Rx only
 - -Dose 10-50 mg at bedtime

Fitzgerald Health Education Associates

- -Onset of action=15-30 mins
- –Peak=2 h
- $-T_{1/2}=3-7$ h




- Diphenhydramine (Benadryl[®])
 - In the majority of OTC sleep aids
 - -Dose=12.5-50 mg

Fitzgerald Health Education Associates


- -Onset of action=15-30 mins
- –Peak=2 h
- −T_{1/2}=2−8 h
 - Up to 13 h in elderly


Fitzgerald Health Education Associates





- Doxylamine
 - -Dose 12.5-25 mg at bedtime
- In OTC sleep aids that do not have diphenhydramine as a primary ingredient
 - $-T_{1/2}=10 h$
 - $-T_{max}=2 h$

Fitzgerald Health Education Associates










Easily-found Online "Ramelteon (Rozerem™) Poppers"

 "The usual dosing is in 8 mg tablets, but people seeking "ramelteon (Rozerem[™]) highs" might take as much as a total of 24–32 mg at a time, mix it with booze or other anti-anxiety benzos or sleep aids (such as zolpidem)... a wonderful weed-like high that lasts about 1 h."

Source: <u>http://www.urbandictionary.com/define.php?term=rozerem</u>

 Fitzgerald Health Education Associates 94



Tasimelteon (continued)

- Dosage
 - 20 mg per day taken before bedtime, at the same time every night
 - Effect typically not seen until weeks or months of regular use

Plant-based Products as Sleep Aids

Kava Kava as Sleep Aid


- Mechanism of action
 - Kavalactones act on limbic system
 - Mixed evidence of impact on GABA, dopamine or opioid receptors


Fitzgerald Health Education Associates


Fitzgerald Health Education Associates

Dose as sleep aid
 180–210 mg at bedtime









End of Presentation Thank you for your time and attention.

Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC, FNAP

www.fhea.com cs@fhea.com

Fitzgerald Health Education Associates

- Images/illustrations: Unless otherwise noted, all images/illustrations are from open sources, such as the CDC or Wikipedia or property of FHEA or author.
- All websites listed active at the time of publication.

Fitzgerald Health Education Associates

Copyright Notice

Copyright by Fitzgerald Health Education Associates All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without permission from Fitzgerald Health Education Associates

> Requests for permission to make copies of any part of the work should be mailed to:

Fitzgerald Health Education Associates 85 Flagship Drive North Andover, MA 01845-6184

Fitzgerald Health Education Associates

Statement of Liability

- The information in this program has been thoroughly researched and checked for accuracy. However, clinical practice and techniques are a dynamic process and new information becomes available daily. Prudent practice dictates that the clinician consult further sources prior to applying information obtained from this program, whether in printed, visual or verbal form.
- Fitzgerald Health Education Associates disclaims any liability, loss, injury or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents of this presentation.

Fitzgerald Health Education Associates

105

103

Fitzgerald Health Education Associates			
85 Flagship Drive North Andover, MA 01845-6154 978.794.8366 Fax-978.794.2455			
Website: fhea.com			
Learning & Testing Center: fhea.com/npexpert			
www.facebook.com/fitzgeraldhealth			
@npcert			
Fitzgerald Health Education Associates 106			